Health Startup Noom Adding GLP-1 Drugs to Med Plan Now
Noom is shifting from psychology-based weight loss to prescription treatments, launching Noom Med in a multi-state ro...
GLP-1
This tag page compiles 4 articles on GLP-1 trends, pricing, and weight-loss stock impacts, helping you understand how drug costs and market moves affect personal finances.
41 articlesNovo Nordisk Slashing Prices Could Boost the Stock
Novo Nordisk slashing prices is drawing attention from investors who wonder how a price cut could actually lift the s...
Better Weight Loss Stock: Novo Nordisk vs Amgen Showdown
The weight loss field is heating up, with Novo Nordisk leading the GLP-1 wave and Amgen pursuing a smaller, more sele...
Forget Ozempic: This High-Flying Device Maker Stands Strong
In a world obsessed with weight-loss drugs, a different growth engine quietly powers ahead. This article explains why...
Novo Nordisk's Diabetes Drug Outshines Ozempic: Buy?
A new diabetes drug from Novo Nordisk could change the GLP-1 landscape. This deep dive breaks down what investors sho...